Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | CES1 | P23141 | 4/20 | 0.45 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11014828 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL388197 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL10929119 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL10914192 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL7671120 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL23015009 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL39035 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL4897794 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL10946456 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR | |
| SCHEMBL39565 | 1.00 | TDP1 (0.53) | TDP1LMNAHSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070366-A | Cyclic RNA compositions and methods | 欧纳医疗公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20250376534-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | ORNA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4634390-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250304994-A1 | Circular RNA Compositions and Methods | ORNA THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250283073-A1 | Circular RNA Compositions and Methods | ORNA THERAPEUTICS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-12297285-B2 | Circular RNA encoding chimeric antigen receptors targeting BCMA | ORNA THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4543912-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | Orna Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119816517-A | Cyclic RNA encoding chimeric antigen receptor targeting BCMA | 奥纳治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-8741966-B2 | Lipid compounds for use in cosmetic products, as food supplement or as a medicament | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-06-03 | — | — | US | disclosed |
| US-8741966-B2 | Lipid compounds for use in cosmetic products, as food supplement or as a medicament | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-06-03 | — | — | US | disclosed |
| US-20100280109-A1 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-04 | — | — | US | disclosed |
| US-20100280109-A1 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-04 | — | — | US | disclosed |
| US-20100280109-A1 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-04 | — | — | US | disclosed |
| EP-2217224-A1 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT | Pronova BioPharma Norge AS (NO) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061208-A1 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| US-4863622-A | THIOFATTY ACID ESTER OR FATTY ACID THIO AMINE | PENNZOIL PRODUCTS COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| US-4000315-A | Cyclopropane esters for the control of mites | ZOECON CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-3957849-A | MITICIDES | ZOECON CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283073-A1 | Circular RNA Compositions and Methods | U2AF1, RBM17, RBM22 | TDP1 2985/4885LMNA 914/4885HSD17B10 3443/4885 |
| US-20250376534-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | RBM17, BCR, BCDIN3D | TDP1 4105/4885LMNA 2788/4885HSD17B10 3236/4885 |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | TDP1 2933/4885LMNA 755/4885HSD17B10 1730/4885 |
| US-12297285-B2 | Circular RNA encoding chimeric antigen receptors targeting BCMA | RBM17, BCR, BCDIN3D | TDP1 4105/4885LMNA 2788/4885HSD17B10 3236/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | TDP1 2933/4885LMNA 755/4885HSD17B10 1730/4885 |
| US-20250304994-A1 | Circular RNA Compositions and Methods | U2AF1, RBM22, RTCB | TDP1 2998/4885LMNA 673/4885HSD17B10 3523/4885 |
| US-20100280109-A1 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT | SGMS1, SGMS2, C1S | TDP1 3554/4885LMNA 2157/4885HSD17B10 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.